Related references
Note: Only part of the references are listed.Risk of major cardiovascular events in patients with psoriasis receiving biologic therapies: a prospective cohort study
W. Rungapiromnan et al.
JOURNAL OF THE EUROPEAN ACADEMY OF DERMATOLOGY AND VENEREOLOGY (2020)
An Integrated Analysis of the Safety of Tofacitinib in Psoriatic Arthritis across Phase III and Long-Term Extension Studies with Comparison to Real-World Observational Data
Gerd R. Burmester et al.
DRUG SAFETY (2020)
Clinical and computed tomographic imaging features of novel coronavirus pneumonia caused by SARS-CoV-2
Yu-Huan Xu et al.
JOURNAL OF INFECTION (2020)
Structural basis for the recognition of SARS-CoV-2 by full-length human ACE2
Renhong Yan et al.
SCIENCE (2020)
The COVID-19 outbreak and rheumatologic skin diseases
Gulhima Arora et al.
DERMATOLOGIC THERAPY (2020)
Priorities for global health community in COVID-19 pandemic
Lidia Rudnicka et al.
DERMATOLOGIC THERAPY (2020)
Prevalence of comorbidities and its effects in patients infected with SARS-CoV-2: a systematic review and meta-analysis
Jing Yang et al.
INTERNATIONAL JOURNAL OF INFECTIOUS DISEASES (2020)
Guselkumab in biologic-naive patients with active psoriatic arthritis (DISCOVER-2): a double-blind, randomised, placebo-controlled phase 3 trial
Philip J. Mease et al.
LANCET (2020)
Guselkumab in patients with active psoriatic arthritis who were biologic-naive or had previously received TNFα inhibitor treatment (DISCOVER-1): a double-blind, randomised, placebo-controlled phase 3 trial
Atul Deodhar et al.
LANCET (2020)
Risk Factors Associated With Acute Respiratory Distress Syndrome and Death in Patients With Coronavirus Disease 2019 Pneumonia in Wuhan, China
Chaomin Wu et al.
JAMA INTERNAL MEDICINE (2020)
Safety results of ixekizumab with 1822.2 patient-years of exposure: an integrated analysis of 3 clinical trials in adult patients with psoriatic arthritis
Bernard Combe et al.
ARTHRITIS RESEARCH & THERAPY (2020)
A rapid advice guideline for the diagnosis and treatment of 2019 novel coronavirus (2019-nCoV) infected pneumonia (standard version)
Ying-Hui Jin et al.
MILITARY MEDICAL RESEARCH (2020)
Ustekinumab Safety in Psoriasis, Psoriatic Arthritis, and Crohn's Disease: An Integrated Analysis of Phase II/III Clinical Development Programs
Subrata Ghosh et al.
DRUG SAFETY (2019)
Methotrexate-associated Lymphoproliferative Disorders in Patients With Rheumatoid Arthritis Clinicopathologic Features and Prognostic Factors
Daisuke Kurita et al.
AMERICAN JOURNAL OF SURGICAL PATHOLOGY (2019)
Profibrotic effect of IL-17A and elevated IL-17RA in idiopathic pulmonary fibrosis and rheumatoid arthritis-associated lung disease support a direct role for IL-17A/IL-17RA in human fibrotic interstitial lung disease
Jie Zhang et al.
AMERICAN JOURNAL OF PHYSIOLOGY-LUNG CELLULAR AND MOLECULAR PHYSIOLOGY (2019)
Methotrexate-Associated Pneumonitis and Rheumatoid Arthritis-Interstitial Lung Disease: Current Concepts for the Diagnosis and Treatment
George E. Fragoulis et al.
FRONTIERS IN MEDICINE (2019)
Long-term experience with apremilast in patients with psoriatic arthritis: 5-year results from a PALACE 1-3 pooled analysis
Arthur Kavanaugh et al.
ARTHRITIS RESEARCH & THERAPY (2019)
Long-term safety of secukinumab in patients with moderate-to-severe plaque psoriasis, psoriatic arthritis, and ankylosing spondylitis: integrated pooled clinical trial and post-marketing surveillance data
A. Deodhar et al.
ARTHRITIS RESEARCH & THERAPY (2019)
Serious infections in patients with self-reported psoriatic arthritis from the Psoriasis Longitudinal Assessment and Registry (PSOLAR) treated with biologics
Christopher T. Ritchlin et al.
BMC RHEUMATOLOGY (2019)
The Lung in Rheumatoid Arthritis Focus on Interstitial Lung Disease
Paolo Spagnolo et al.
ARTHRITIS & RHEUMATOLOGY (2018)
A review of ixekizumab in the treatment of psoriatic arthritis
Darren D. O'Rielly et al.
EXPERT REVIEW OF CLINICAL IMMUNOLOGY (2018)
Apremilast: A Novel Oral Treatment for Psoriasis and Psoriatic Arthritis
Tiago Torres et al.
AMERICAN JOURNAL OF CLINICAL DERMATOLOGY (2018)
Phosphodiesterase 4 inhibition reduces lung fibrosis following targeted type II alveolar epithelial cell injury
Thomas H. Sisson et al.
PHYSIOLOGICAL REPORTS (2018)
Psoriatic Arthritis
Christopher T. Ritchlin et al.
NEW ENGLAND JOURNAL OF MEDICINE (2017)
Tofacitinib for Psoriatic Arthritis in Patients with an Inadequate Response to TNF Inhibitors
Dafna Gladman et al.
NEW ENGLAND JOURNAL OF MEDICINE (2017)
Safety and Efficacy of Intravenous Golimumab in Patients With Active Psoriatic Arthritis Results Through Week Twenty-Four of the GO-VIBRANT Study
Arthur Kavanaugh et al.
ARTHRITIS & RHEUMATOLOGY (2017)
Tumor necrosis factor inhibitors in psoriatic arthritis
Santhi Mantravadi et al.
EXPERT REVIEW OF CLINICAL PHARMACOLOGY (2017)
Candida infections in patients with psoriasis and psoriatic arthritis treated with interleukin-17 inhibitors and their practical management
D. M. Saunte et al.
BRITISH JOURNAL OF DERMATOLOGY (2017)
European League Against Rheumatism (EULAR) recommendations for the management of psoriatic arthritis with pharmacological therapies: 2015 update
L. Gossec et al.
ANNALS OF THE RHEUMATIC DISEASES (2016)
Protective Effect of Infliximab, a Tumor Necrosis Factor-Alfa Inhibitor, on Bleomycin-Induced Lung Fibrosis in Rats
Nejat Altintas et al.
INFLAMMATION (2016)
Group for Research and Assessment of Psoriasis and Psoriatic Arthritis 2015 Treatment Recommendations for Psoriatic Arthritis
Laura C. Coates et al.
ARTHRITIS & RHEUMATOLOGY (2016)
The effects of tumour necrosis factor inhibitors, methotrexate, non-steroidal anti-inflammatory drugs and corticosteroids on cardiovascular events in rheumatoid arthritis, psoriasis and psoriatic arthritis: a systematic review and meta-analysis
Camille Roubille et al.
ANNALS OF THE RHEUMATIC DISEASES (2015)
Secukinumab Inhibition of Interleukin-17A in Patients with Psoriatic Arthritis
Philip J. Mease et al.
NEW ENGLAND JOURNAL OF MEDICINE (2015)
Efficacy and safety of the anti-IL-12/23 p40 monoclonal antibody, ustekinumab, in patients with active psoriatic arthritis despite conventional non-biological and biological anti-tumour necrosis factor therapy: 6-month and 1-year results of the phase 3, multicentre, double-blind, placebo-controlled, randomised PSUMMIT 2 trial
Christopher Ritchlin et al.
ANNALS OF THE RHEUMATIC DISEASES (2014)
Ustekinumab, an anti-IL-12/23 p40 monoclonal antibody, inhibits radiographic progression in patients with active psoriatic arthritis: results of an integrated analysis of radiographic data from the phase 3, multicentre, randomised, double-blind, placebo-controlled PSUMMIT-1 and PSUMMIT-2 trials
Arthur Kavanaugh et al.
ANNALS OF THE RHEUMATIC DISEASES (2014)
Methotrexate and Lung Disease in Rheumatoid Arthritis
Richard Conway et al.
ARTHRITIS & RHEUMATOLOGY (2014)
Meta-analysis of psoriasis, cardiovascular disease, and associated risk factors
Iben Marie Miller et al.
JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY (2013)
A randomized placebo-controlled trial of methotrexate in psoriatic arthritis
Gabrielle H. Kingsley et al.
RHEUMATOLOGY (2012)
Blocking IL-17A Promotes the Resolution of Pulmonary Inflammation and Fibrosis Via TGF-β1-Dependent and -Independent Mechanisms
Su Mi et al.
JOURNAL OF IMMUNOLOGY (2011)
The risk of tuberculosis related to tumour necrosis factor antagonist therapies: a TBNET consensus statement
I. Solovic et al.
EUROPEAN RESPIRATORY JOURNAL (2010)
Sensitivity of the Classification of Psoriatic Arthritis Criteria in Early Psoriatic Arthritis
Salvatore D'Angelo et al.
JOURNAL OF RHEUMATOLOGY (2009)
Classification criteria for psoriatic arthritis - Development of new criteria from a large international study
William Taylor et al.
ARTHRITIS AND RHEUMATISM (2006)
Toxicity of methotrexate treatment in psoriasis and psoriatic arthritis - Short- and long-term toxicity in 104 patients
U Wollina et al.
CLINICAL RHEUMATOLOGY (2001)
Share Paper
